Estrogen Priming in Advanced Breast Cancer-Reference-Cited by-同舟云学术

Estrogen Priming in Advanced Breast Cancer

Published:1988-09 Issue:9 Volume:22 Page:672-675
ISSN:0012-6578
Container-title:Drug Intelligence & Clinical Pharmacy
language:en
Short-container-title:Drug Intelligence & Clinical Pharmacy

Author:

Maghsoodnia Maziar¹,Holleran Walter M.²,DeGregorio Michael W.³

Affiliation:

1. Doctor of Pharmacy Student, School of Pharmacy, University of California, San Francisco

2. Cancer Research Institute, University of California, San Francisco

3. Cancer Pharmacokinetics Laboratory, Cancer Research Institute, University of California, San Francisco, and the Children's Cancer Research Institute, Pacific Presbyterian Medical Center, San Francisco, CA

Abstract

The successful treatment of advanced breast cancer has reached a plateau in recent years. Estrogen priming is a new combination therapy involving estrogens, antiestrogens, and chemotherapy that may result in the improvement of treatment responses. This investigational therapy is designed to synchronize cell cycles with estrogens and antiestrogens in order to enhance the activity of cell cycle-specific anticancer drugs. The pharmacological manipulation of cell growth coupled with appropriate antineoplastic agents could result in a new treatment approach for advanced breast cancer. The rationale and current status of estrogen priming are reviewed.

Publisher

SAGE Publications

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Link

http://journals.sagepub.com/doi/pdf/10.1177/106002808802200903

Reference27 articles.

1. Cancer Statistics, 1987

2. Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study

3. High-dose chemotherapy for breast cancer.

4. Adjuvant systemic therapy for resectable breast cancer.